Related Experiment Video
Updated: May 12, 2026
05:14
Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Published on: August 11, 2023
Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010
Salomon Y Cohen1, Lise Dubois, Sandrine Ayrault
1Centre Ophtalmologique d'Imagerie et de Laser, 11 Rue Antoine Bourdelle, Paris, 75015, France, sycsyc75@gmail.com.
Summary
Improved visual outcomes in exudative age-related macular degeneration (AMD) were observed with ranibizumab treatment in 2010 compared to 2007. This gain is likely due to an increased number of intravitreal injections (IVT) administered.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background:
- Monthly follow-up is crucial for optimal visual results with pro re nata ranibizumab treatment for exudative age-related macular degeneration (AMD).
- A previous study in 2007 indicated suboptimal visual gains (+0.7 ETDRS letters) potentially due to insufficient follow-up and injections.
Purpose of the Study:
- To evaluate if changes in AMD patient management between 2007 and 2010 improved visual outcomes.
- To compare visual results of ranibizumab treatment administered after April 1, 2010, with a prior 2007 cohort.
Main Methods:
- Retrospective analysis of 122 patients (125 eyes) with exudative AMD treated in 2010.
- Data collected included age, gender, eye side, CNV type, visual acuity (VA) at baseline and 52 weeks, number of intravitreal injections (IVT), and follow-up visits.
- Statistical comparison with a 2007 cohort using Mann-Whitney, Fisher's exact, and chi-square tests.
Main Results:
- The 2010 series showed a mean visual gain of +6.0 ETDRS letters, with an average of 5.0 IVT and 7.8 follow-up visits.
- Patients in 2010 were older and had better baseline VA than in 2007, yet achieved significantly better visual results (+6.0 vs +0.7 letters, p=0.0003).
- A reverse correlation was noted between baseline VA and visual gain (r=-0.413, p<0.0001).
Conclusions:
- Monotherapy with ranibizumab for exudative AMD yielded superior visual results in 2010 compared to 2007 in the studied clinical setting.
- Increased number of IVT in 2010 is a probable factor contributing to the improved visual outcomes.
- Alternative strategies like "inject and extend" or maintenance therapy may also play a role in enhanced visual results.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...